Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Aflibercept
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Alvotech
Deal Size : Undisclosed
Deal Type : Agreement
Details : According to the agreement, Alvotech will be responsible for development and manufacture, while Polifarma will handle market registration and commercialization of AVT06, a recombinant fusion protein and a biosimilar candidate to Eylea® (aflibercept).
Product Name : AVT06
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
October 05, 2023
Lead Product(s) : Aflibercept
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Alvotech
Deal Size : Undisclosed
Deal Type : Agreement